中文
About Us
Corporate Overview
Management Team
Board of Directors
Contact Us
Our Focus
Metabolic Diseases
Immune Diseases
Exploratory Indications
Pipeline
Pipeline
Clinical Trials
Partnership
Investors
Financials & Filing
Upcoming Events
Corporate presentation
SCIENTIFIC PRESENTATIONS
News
Careers
Our Focus
Metabolic Diseases
Immune Diseases
Exploratory Indications
Boyle, JG, et al., Clinical Science (2018) 132 1699–1709
Publications
Title
Venue
Type
Date
ASC36, a Once-Monthly Next-Generation Amylin Receptor Agonist Peptide, demonstrated 32-day average observed half-life, 6-fold longer than petrelintide, in NHP model and 91% more relative weight loss than petrelintide in DIO rat model
The 33rd European Congress on Obesity
(ECO 2026)
Poster
5/2026
ASC35, a Once-Monthly Next-Generation GLP-1R/GIPR Dual Agonist Peptide, demonstrated 14-day average observed half-life, 6-fold longer than tirzepatide, in NHP model and 71% more relative weight loss than tirzepatide in DIO mouse model
The 33rd European Congress on Obesity
(ECO 2026)
Poster
5/2026
ASC47 in Combination with Semaglutide Demonstrated Up to 111.8% Greater Relative Weight loss in Participants with Obesity Compared to Semaglutide Monotherapy
The 33rd European Congress on Obesity
(ECO 2026)
Poster
5/2026
GLP-1R/GIPR Peptide Agonist ASC31 + ASC47 Shows 119.6% More Weight Loss than Tirzepatide in DIO Mice
ObesityWeek® 2025
Poster
11/2025
A full analysis of 28-Day MAD Study of Oral GLP-1R Biased Small Molecule Agonist ASC30 for obesity
ObesityWeek® 2025
Poster
11/2025
ASC30, a Once-Monthly SQ Injected Small Molecule GLP-1RA in Participants with Obesity:A Ph Ib Study
ObesityWeek® 2025
Poster
11/2025
ASC30, an Oral GLP-1R Biased Small Molecule Agonist Demonstrated Superior Weigh Loss in Participants with Obesity: A 28-Day Multiple Ascending Dose Study
The 61st European Association for the Study of Diabetes
(EASD 2025)
Short Oral Presentation
9/2025
ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Preclinical Model
The American Diabetes Association's 85th Scientific Sessions
(ADA 2025)
Poster
6/2025
ASC30, an Oral GLP-1R Biased Small Molecule Agonist in Participants with Obesity—A First-in-Human Single Ascending Dose Study
The American Diabetes Association's 85th Scientific Sessions
(ADA 2025)
Poster
6/2025
ASC47, a Muscle-Preserving Weight Loss Drug Candidate in Healthy Participants: A First-in-human Single Ascending Dose Study
The 32nd European Congress On Obesity (ECO 2025)
Guided poster
5/2025
ASC47, An Adipose-Targeted, Muscle-Preserving Weight Loss Drug Candidate For Obesity, Demonstrated Significant Weight Loss And Preserved Muscle In DIO Mice
The 32nd European Congress On Obesity (ECO 2025)
Oral
5/2025
浙公网安备 33010802003344号 浙ICP备11050387号-1